Outcome of Board Meeting - Board approves Dividend
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tatva Chintan Pharma Chem's Board meeting on 16 May 2026 approved and took on record the audited financial results for Q4 and full year ended 31 March 2026. Standalone profit after tax for FY 2025-26 stood at Rs. 390.82 million versus Rs. 1.10 million in FY 2024-25, a significant recovery. Consolidated profit after tax was Rs. 420.54 million. Total standalone income from operations was Rs. 4,962.96 million (up from Rs. 3,664.15 million). The Board recommended a final dividend of Rs. 2 per equity share (20% on Rs. 10 face value), subject to shareholder approval at the ensuing AGM. The company also appointed new Cost Auditor (M/s. Zarna Thakar & Associates) and Internal Auditor (RSM Astute Consultech Private Limited) for FY 2026-27.
Strong recovery in profitability with PAT jumping significantly year-on-year. The dividend declaration signals management confidence, though the Rs. 2/share payout is modest given the current EPS of Rs. 16.71 on standalone basis. Shareholders should watch for the record date announcement for dividend eligibility at the upcoming AGM.